Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Transpl Infect Dis. 2020 Dec 7;23(2):e13514. doi: 10.1111/tid.13514

Figure 6. Transplant vascular sclerosis is decreased in clodronate-liposome treated LDI allografts.

Figure 6.

TVS was quantified in Cohort #2 recipients to compare the degree of vascular disease present in allograft vessels between clodronate and control liposomes treated animals treated animals. LDI F344 rats were treated with either control liposomes (black) or clodronate liposomes (red) three days prior to heterotopic heart allograft transplant into RCMV naïve Lewis recipients. Recipients (n=5 per group/time point) were euthanized on POD 7, 14, 21, and 28 at which time rat tissues and heart allografts were collected for analysis. Embedded allograft heart tissues were sectioned and stained with H&E and elastin to visualize vessel neointimal formation. Panel A depicts graphical representation of TVS quantification as reported as the mean allograft NI. Images shown in Panel B shows representative stained graft heart tissue sections. Clodronate liposome treated allografts have reduced TVS relative to control liposome treated allografts starting at POD14 and persisting through POD28 *p≤0.05, **p≤0.01 as determined by Student’s t- test.